Literature DB >> 8706260

Persistent chemopreventive effect of S-adenosyl-L-methionine on the development of liver putative preneoplastic lesions induced by thiobenzamide in diethylnitrosamine-initiated rats.

M M Simile1, M Saviozzi, M R De Miglio, M R Muroni, A Nufris, R M Pascale, G Malvaldi, F Feo.   

Abstract

S-Adenosyl-L-methionine (SAM) is a strong chemopreventive agent of rat liver carcinogenesis. Examination was made to determine whether inhibition by SAM of the development of preneoplastic liver lesions persists to SAM withdrawal in diethylnitrosamine-initiated F344 rats promoted with thiobenzamide (TB). The rats were subjected, 2 weeks after initiation, to 5 weeks feeding with a 0.1% TB diet followed by a TB-free diet for 6 weeks and then a second TB treatment for 3 weeks. SAM (384 micromol/kg/day) was injected i.m. during the first TB cycle (treatment A) or for 6 weeks after the first TB cycle (treatment B). Many gamma-glutamyltranspeptidase (GGT)-positive lesions developed in initiated rats after the first TB cycle. They decreased in number after TB withdrawal, while partial recovery of lesion number and a great increase in volume occurred after the second TB cycle. Liver ornithine decarboxylase (ODC) activity and c-myc and c-Ha-ras mRNAs increased during the TB cycles and returned to normal liver values after TB withdrawal. Number and size of GGT-positive lesions, DNA synthesis of GGT-positive cells, liver ODC activity and c-myc and c-Ha-ras mRNA levels decreased as a consequence of SAM treatment A. The recovery of these parameters, induced by a second TB cycle in rats not treated with SAM, was prevented by SAM treatment B. These results suggest that SAM causes a persistent decrease in growth capacity of preneoplastic liver lesions in rats subjected to a diethylnitrosamine/TB protocol.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8706260     DOI: 10.1093/carcin/17.7.1533

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  4 in total

Review 1.  Deregulation of methionine metabolism as determinant of progression and prognosis of hepatocellular carcinoma.

Authors:  Rosa M Pascale; Claudio F Feo; Diego F Calvisi; Francesco Feo
Journal:  Transl Gastroenterol Hepatol       Date:  2018-06-29

2.  A Phase II Randomized, Controlled Trial of S-Adenosylmethionine in Reducing Serum α-Fetoprotein in Patients with Hepatitis C Cirrhosis and Elevated AFP.

Authors:  Timothy R Morgan; Kathryn Osann; Teodoro Bottiglieri; Neville Pimstone; John C Hoefs; Ke-Qin Hu; Tarek Hassanein; Thomas D Boyer; Lorene Kong; Wen-Pin Chen; Ellen Richmond; Rachel Gonzalez; Luz M Rodriguez; Frank L Meyskens
Journal:  Cancer Prev Res (Phila)       Date:  2015-06-30

Review 3.  Experimental Models to Define the Genetic Predisposition to Liver Cancer.

Authors:  Rosa M Pascale; Maria M Simile; Graziella Peitta; Maria A Seddaiu; Francesco Feo; Diego F Calvisi
Journal:  Cancers (Basel)       Date:  2019-09-27       Impact factor: 6.639

Review 4.  S-Adenosylmethionine: From the Discovery of Its Inhibition of Tumorigenesis to Its Use as a Therapeutic Agent.

Authors:  Rosa M Pascale; Maria M Simile; Diego F Calvisi; Claudio F Feo; Francesco Feo
Journal:  Cells       Date:  2022-01-25       Impact factor: 6.600

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.